Three insights:
1. IDCT is an injectable cell therapy that use progenitor cells — known as Discogenic Cells — to provide a regenerative solution for the treatment of mild to moderate degenerative disc disease.
2. Its biomedically engineered progenitor cells are derived from intervertebral disc tissue and offer a non-invasive approach to treating the condition.
3. IDCT is currently being evaluated in clinical trials in the U.S. and Japan.
More articles on devices:
Colorado health system building orthopedic, sports medicine practice
Aurora Spine posts $3.2M in Q2 revenue: 6 things to know
Dr. Thomas Parisi, patient travel to Mexico for total knee replacement where it costs $18,000 less
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
